Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises BICO in connection with a directed issue of new shares for SEK 2 billion
Mandate

Vinge advises BICO in connection with a directed issue of new shares for SEK 2 billion

October 08, 2021 Capital Markets and Public M&A

Vinge has advised BICO Group AB in connection with a directed issue of new shares for approximately SEK 2 billion.

The subscription price of SEK 480 was set pursuant to an accelerated bookbuilding procedure arranged by Carnegie, J.P. Morgan, ABG and Bryan Garnier. BICO intends to use the issue proceeds to finance the acquisition of QInstruments as well as to further promote the Company’s acquisition agenda and create financial preparedness regarding new possibilities.

Vinge’s team consisted of Anders Strid, Edin Agic and Adrian Filipovic.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025